泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03347 泰格医药

未开盘 07-22 16:08:56

31.050

+1.150

+3.85%

最高31.450	最低29.900	成交量166.08万
今开30.400	昨收29.900	日振幅5.18%
总市值268.57亿	流通市值38.19亿	总股本8.65亿
成交额5,152万	换手率1.35%	流通股本1.23亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03347","market":"HK","secType":"STK","nameCN":"泰格医药","latestPrice":31.05,"timestamp":1721635736030,"preClose":29.9,"halted":0,"volume":1660764,"delay":0,"floatShares":123000000,"shares":864948570,"eps":2.5051699,"marketStatus":"未开盘","marketStatusCode":0,"change":1.15,"latestTime":"07-22 16:08:56","open":30.4,"high":31.45,"low":29.9,"amount":51519239,"amplitude":0.051839,"askPrice":31.1,"askSize":8100,"bidPrice":31.05,"bidSize":5500,"shortable":3,"etf":0,"ttmEps":2.085994191614943,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721698200000},"adr":0,"listingDate":1596729600000,"adjPreClose":29.9,"dividendRate":0.01961,"openAndCloseTimeList":[[1721611800000,1721620800000],[1721624400000,1721635200000]],"volumeRatio":1.342831,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"300347","market":"SZ","secType":"STK","nameCN":"泰格医药","latestPrice":54.21,"timestamp":1721631828000,"preClose":52.05,"halted":0,"volume":10146266,"delay":0,"premium":"-46.48"}},"requestUrl":"/m/hq/s/03347/wiki","defaultTab":"wiki","newsList":[{"id":"2453756713","title":"赛升药业(300485.SZ)：人源化抗VEGF单抗注射液临床试验获伦理委员会审批报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2453756713","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453756713?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:53","pubTimestamp":1721638403,"startTime":"0","endTime":"0","summary":"智通财经APP讯，赛升药业(300485.SZ)公告，公司研制的“人源化抗VEGF单抗注射液”获得国家癌症中心/中国医学科学院北京协和医学院肿瘤医院伦理委员会审批报告。该药品适应症为转移性结直肠癌等，本次获同意的项目名称为：比较人源化抗VEGF单抗或贝伐珠单抗分别联合奥沙利铂和氟尿嘧啶类一线治疗转移性结直肠癌的有效性、安全性及免疫原性的随机、双盲、平行对照的III期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1141","03347","BK0012","300485","BK0239","BK1576","BK0028","BK0046"],"gpt_icon":0},{"id":"2453598756","title":"泰格医药(03347)7月22日斥资270.83万元回购5万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453598756","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453598756?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:40","pubTimestamp":1721637643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，该公司于2024年7月22日斥资人民币270.83万元回购5万股A股，每股回购价格为人民币54.14-54.25元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153879.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0174","BK1576","BK0216","LU1820825898.SGD","399300","BK1141","159982","BK0077","BK0028","LU1146622755.USD","03347","300347","BK1583"],"gpt_icon":0},{"id":"2453731253","title":"龙头业绩预喜！CRO概念股集体狂飙，机构：全面看多下半年医药行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2453731253","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453731253?lang=zh_cn&edition=full","pubTime":"2024-07-22 14:44","pubTimestamp":1721630654,"startTime":"0","endTime":"0","summary":"有望迎来边际改善","market":"sg","thumbnail":"https://img3.gelonghui.com/ace7d-6b3066d4-036c-4224-b3e3-aa509104a112.jpg?guru_height=812&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/ace7d-6b3066d4-036c-4224-b3e3-aa509104a112.jpg?guru_height=812&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/870710","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU0043850808.USD","LU1242518857.USD","BK1515","LU0359201612.USD","BK1610","LU2045819591.USD","LU0819121731.USD","LU0039217434.USD","06821","LU1720050803.USD","LU0307460666.USD","BK1141","BK0216","LU2125910500.SGD","LU0181495838.USD","02359","BK1191","SG9999002562.SGD","LU0516423174.USD","LU1046422090.SGD","03759","LU0823426308.USD","01873","03347","LU0572944931.SGD","SG9999002463.SGD","BK1574","LU0326950275.SGD","LU0052750758.USD","BK1576","LU0051755006.USD","LU0516423091.SGD","LU0708995583.HKD","BK1521","02269","LU0588546209.SGD","301333","09939","LU0823426480.USD","603127","LU0348825331.USD","LU0348735423.USD","BK1589","LU0456827905.SGD","LU0516422952.EUR","LU0979878070.USD","LU1880383366.USD","LU1794554557.SGD","LU2242644610.SGD","BK1583"],"gpt_icon":0},{"id":"2453735655","title":"强化肾病和自免疫疾病领域领先优势 云顶新耀-B(01952)同类首创药物泽托佐米治疗狼疮性肾炎的临床试验完成中国首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2453735655","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453735655?lang=zh_cn&edition=full","pubTime":"2024-07-22 13:35","pubTimestamp":1721626553,"startTime":"0","endTime":"0","summary":"7月22日，港股上市创新药企云顶新耀-B(01952)宣布，其同类首创药物泽托佐米(zetomipzomib)治疗活动性狼疮性肾炎(LN)的全球2b期PALIZADE试验已完成中国首例患者给药。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20240722/20240722133623_72715.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240722/20240722133623_72715.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1141","BK1161","03347","BK1576","01952","BK1583","BK1574"],"gpt_icon":0},{"id":"2453789272","title":"泰格医药(03347)上涨5.02%，报31.4元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453789272","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453789272?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:49","pubTimestamp":1721616557,"startTime":"0","endTime":"0","summary":"7月22日，泰格医药(03347)盘中上涨5.02%，截至10:49，报31.4元/股，成交2337.37万元。杭州泰格医药科技股份有限公司是一家提供全周期生物医药研发服务的公司，主要为全球制药和医疗器械行业提供创新研发解决方案。公司通过其100多家子公司，打造了一个覆盖全产业链的创新生态，致力于解决全球健康问题，满足患者的医疗需求。截至2024年一季报，泰格医药营业总收入16.6亿元、净利润2.35亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/22104941702228.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","300347","BK0216","LU1820825898.SGD","BK1141","BK0077","BK0028","LU1146622755.USD","03347","BK0174","BK1583"],"gpt_icon":0},{"id":"2453653781","title":"泰格医药盘中异动 急速上涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453653781","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453653781?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:47","pubTimestamp":1721616473,"startTime":"0","endTime":"0","summary":"2024年07月22日早盘10时47分，泰格医药股票出现波动，股价快速拉升5.02%。截至发稿，该股报31.400港元/股，成交量74.27万股，换手率0.60%，振幅5.02%。泰格医药股票所在的生物技术行业中，整体涨幅为0.65%。其相关个股中，华领医药-B、盛禾生物-B、维亚生物涨幅较大，振幅较大的相关个股有华领医药-B、维亚生物、科伦博泰生物-B，振幅分别为15.70%、7.07%、7.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722104754af9356dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240722104754af9356dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1576","BK1583","BK1141"],"gpt_icon":0},{"id":"2453891127","title":"医药外包概念普涨 康龙化成(03759)涨6.66% 东方证券料板块有望迎来边际改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2453891127","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453891127?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:40","pubTimestamp":1721616006,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念普涨，截至发稿，康龙化成 涨6.66%，维亚生物涨5.05%，泰格医药涨2.84%，药明生物涨2.77%。该行认为，CXO板块在经历业绩、估值双杀之后，有望迎来边际改善。方正证券认为，国内CXO企业正快步向新兴领域延伸，拓展新品类，并加快相关布局，希望承接全球相关产能需求，在未来五年的成长之路收获新增量。此外，头部企业康龙化成发布盈喜，截至2024年6月30日的半年度业绩预告。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NjUzMWVjZjQ5MDRjNGY2OWIzOTk1NmJhNzg4ZTIwMmI4MTQyOTUwMDc1MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjUzMWVjZjQ5MDRjNGY2OWIzOTk1NmJhNzg4ZTIwMmI4MTQyOTUwMDc1MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1940780","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03347","BK1574","LU0516422440.USD","LU0417516902.SGD","LU0516423091.SGD","BK0216","09939","01873","300759","LU0417516738.SGD","BK1161","BK0183","BK0188","BK1141","LU1794554557.SGD","LU1880383366.USD","LU1688375341.USD","02269","BK1576","LU0051755006.USD","600958","LU0327786744.USD","SG9999002562.SGD","BK1610","BK1583","159938","LU0856984785.SGD","LU0456827905.SGD","LU0043850808.USD","LU0359201612.USD","LU2039709279.SGD","SG9999002463.SGD","03958","LU0823426480.USD","LU0052750758.USD","BK1147","LU0320764599.SGD","LU0348735423.USD","LU0819121731.USD","LU0516423174.USD","LU0979878070.USD","BK1521","03759","BK0276","LU0181495838.USD","LU0359202008.SGD","BK1589","LU0348825331.USD","LU0823426308.USD","LU0572944931.SGD"],"gpt_icon":0},{"id":"2453785081","title":"港股异动 | CRO概念股集体上涨 头部公司新签订单金额双位数增长 板块有望迎来边际改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2453785081","media":"智通财经","labels":["Business Data"],"top":-1,"share":"https://www.laohu8.com/m/news/2453785081?lang=zh_cn&edition=full","pubTime":"2024-07-22 10:10","pubTimestamp":1721614253,"startTime":"0","endTime":"0","summary":"从上半年整体来看，预计公司营业收入同比阶段性略有下降；公司全球客户询单和访问同比有所回暖，新签订单金额同比增长超过15%。此前，凯莱英公布上半年新签订单同比增长超过20%。该行认为，CXO板块在经历业绩、估值双杀之后，有望迎来边际改善。方正证券认为，国内CXO企业正快步向新兴领域延伸，拓展新品类，并加快相关布局，希望承接全球相关产能需求，在未来五年的成长之路收获新增量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0051755006.USD","SG9999002562.SGD","LU0979878070.USD","LU0052750758.USD","BK1589","LU0516423174.USD","LU1242518931.SGD","LU0043850808.USD","BK1583","HSTECH","LU0039217434.USD","LU1688375341.USD","LU0181495838.USD","LU0307460666.USD","LU0320764599.SGD","LU0588546209.SGD","03347","01548","SG9999002463.SGD","YANG","LU0516422366.SGD","LU0417516738.SGD","LU0516422952.EUR","LU0456846285.SGD","LU0572944931.SGD","LU0516422440.USD","LU0823426480.USD","LU1242518857.USD","HK0000320223.HKD","IE00B0JY6N72.USD","LU0708995583.HKD","03759","LU0359201612.USD","LU0326950275.SGD","BK1141","LU0348735423.USD","02269","LU0140636845.USD","BK1521","LU0516423091.SGD","HSCEI","LU1720050803.USD","LU0417516902.SGD","LU0348825331.USD","LU0819121731.USD","LU1794554557.SGD","LU0327786744.USD","LU2039709279.SGD","BK1576"],"gpt_icon":1},{"id":"2453422307","title":"恒瑞医药(600276.SH)及子公司获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2453422307","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453422307?lang=zh_cn&edition=full","pubTime":"2024-07-21 16:28","pubTimestamp":1721550493,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)公告，近日，公司及子公司山东盛迪医药有限公司收到国家药品监督管理局(简称“国家药监局”)核准签发关于羟乙磺酸达尔西利片、HRS-1358片的《药物临床试验批准通知书》，将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定，经审查，2024年4月23日受理的羟乙磺酸达尔西利片和2024年4月19日受理的HRS-1358片临床试验申请符合药品注册的有关要求，同意羟乙磺酸达尔西利片联合HRS-1358片开展用于乳腺癌的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153604.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","LU1328615791.USD","600276","BK1141","BK0060","LU2148510915.USD","03347","BK0183","LU0405327494.USD","LU0405327148.USD","BK0239","BK1576","BK0188","BK0028","LU1064131003.USD","BK0012","LU2488822045.USD","BK0196","BK1583"],"gpt_icon":0},{"id":"2453223091","title":"恒瑞医药(600276.SH)：海曲泊帕乙醇胺片获药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2453223091","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453223091?lang=zh_cn&edition=full","pubTime":"2024-07-21 16:25","pubTimestamp":1721550354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)公告，公司收到国家药品监督管理局(简称“国家药监局”)核准签发关于海曲泊帕乙醇胺片的《药物临床试验批准通知书》，将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定，经审查，2024年4月17日受理的海曲泊帕乙醇胺片临床试验申请符合药品注册的有关要求，同意本品开展“计划接受有创性操作或手术的慢性肝病伴血小板减少症的成年患者”的临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK0060","BK0183","BK0239","BK1583","LU2148510915.USD","600276","BK1141","LU1328615791.USD","BK0188","03347","LU1064131003.USD","LU2488822045.USD","LU0405327494.USD","BK0012","BK0028","BK0196","LU1064130708.USD","LU0405327148.USD"],"gpt_icon":0},{"id":"2452344094","title":"华润双鹤最新公告：公司司美格鲁肽注射液完成I期临床试验 计划开展Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2452344094","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452344094?lang=zh_cn&edition=full","pubTime":"2024-07-19 17:19","pubTimestamp":1721380778,"startTime":"0","endTime":"0","summary":"华润双鹤公告，司美格鲁肽注射液于2024年7月16日完成I期临床试验；参照生物类似药临床试验设计指导原则，无需进行II期探索性临床试验；2024年7月18日Ⅲ期临床试验登记公示，计划开展Ⅲ期临床试验。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071900037769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0185","BK1583","BK0175","BK0028","BK0188","BK1141","BK0239","03347","BK1576","600062"],"gpt_icon":0},{"id":"2452171442","title":"泰格医药(03347)7月19日斥资273.24万元回购5.25万股A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452171442","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452171442?lang=zh_cn&edition=full","pubTime":"2024-07-19 17:15","pubTimestamp":1721380546,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰格医药(03347)发布公告，该公司于2024年7月19日斥资人民币273.24万元回购5.25万股A股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153208.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK1576","03347","BK0077","159982","BK0216","BK1583","BK1141","300347","LU1146622755.USD","LU1820825898.SGD","BK0174","399300"],"gpt_icon":0},{"id":"2452442676","title":"华润双鹤(600062.SH)：司美格鲁肽注射液完成I期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2452442676","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452442676?lang=zh_cn&edition=full","pubTime":"2024-07-19 17:14","pubTimestamp":1721380451,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华润双鹤(600062.SH)发布公告，公司司美格鲁肽注射液于2024年7月16日完成I期临床试验;参照生物类似药临床试验设计指导原则，无需进行II期探索性临床试验;2024年7月18日Ⅲ期临床试验登记公示，计划开展Ⅲ期临床试验。据悉，司美格鲁肽注射液适用于成人2型糖尿病患者的血糖控制：在饮食控制和运动基础上，接受二甲双胍和/或磺脲类药物治疗血糖仍控制不佳的成人2型糖尿病患者。适用于降低伴有心血管疾病的2型糖尿病成人患者的主要心血管不良事件(心血管死亡、非致死性心肌梗死或非致死性卒中)风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1153205.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK1576","03347","BK0185","BK0188","BK1583","BK1141","BK0010","BK0175","BK0239","600062"],"gpt_icon":0},{"id":"2452056492","title":"CRO概念盘中拉升，海特生物涨3.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452056492","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452056492?lang=zh_cn&edition=full","pubTime":"2024-07-19 11:21","pubTimestamp":1721359298,"startTime":"0","endTime":"0","summary":"07月19日，CRO概念盘中拉升，截至11点21分，CRO概念整体指数上涨1.01%，报332.680点。从个股上来看，该概念的成分股中，海特生物涨3.73%，皓元医药、泰格医药、美迪西涨幅居前。从资金上来看，截止发稿，CRO概念主力净流入为-4689.04万，其中泰格医药受到资金热捧，主力净流入2076.15万；拉长时间线来看，该板块近20日主力资金净流入-25.96亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719112138aefa6f44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719112138aefa6f44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347"],"gpt_icon":0},{"id":"2452493802","title":"南向资金7月18日净买入泰格医药8.67万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2452493802","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452493802?lang=zh_cn&edition=full","pubTime":"2024-07-19 09:31","pubTimestamp":1721352698,"startTime":"0","endTime":"0","summary":"7月18日, 南向资金增持泰格医药8.67万股，连续3日增持。截止当日收盘，港股通共持有泰格医药6320.13万股，占流通股51.32%。港股通增持金额前五个股分别为腾讯控股、中国移动、中国平安、中国石油化工股份、小米集团-W。泰格医药近5个交易日上涨2.97%，港股通累计增持38.55万股；近20个交易日下跌2.96%，港股通累计减持37.69万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190943259f6873fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190943259f6873fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1141","BK1576","BK1583","03347"],"gpt_icon":0},{"id":"2452493807","title":"泰格医药7月18日遭北向资金减持101.85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452493807","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452493807?lang=zh_cn&edition=full","pubTime":"2024-07-19 09:31","pubTimestamp":1721352677,"startTime":"0","endTime":"0","summary":"7月18日，北向资金减持泰格医药101.85万股。截止当日收盘，深股通共持有泰格医药2296.87万股，占流通股3.09%。深股通减持金额前五个股分别为中际旭创、立讯精密、五粮液、阳光电源、卫星化学。泰格医药近5个交易日上涨4.81%，深股通累计增持217.50万股；近20个交易日上涨1.27%，深股通累计增持57.92万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190939299f686ea1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407190939299f686ea1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","03347","BK1141","BK1583"],"gpt_icon":0},{"id":"2452483398","title":"安科生物最新公告：AFN0328注射液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2452483398","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452483398?lang=zh_cn&edition=full","pubTime":"2024-07-18 20:10","pubTimestamp":1721304632,"startTime":"0","endTime":"0","summary":"安科生物公告，近日，安徽安科生物工程(集团)股份有限公司收到国家药品监督管理局下发的《药物临床试验批准通知书》，公司与参股公司合肥阿法纳生物科技有限公司(以下简称“阿法纳公司”)、合肥阿法纳安科生物科技有限公司联合申报的“AFN0328注射液”治疗恶性肿瘤的临床试验申请已获批准。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071800041899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK1576","03347","BK0042","BK1583","300009","BK0070","BK0239","BK1141"],"gpt_icon":0},{"id":"2452310982","title":"安科生物(300009.SZ)：AFN0328注射液治疗恶性肿瘤临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2452310982","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452310982?lang=zh_cn&edition=full","pubTime":"2024-07-18 18:31","pubTimestamp":1721298677,"startTime":"0","endTime":"0","summary":"智通财经APP讯，安科生物(300009.SZ)公告，公司收到国家药品监督管理局下发的《药物临床试验批准通知书》，公司与参股公司合肥阿法纳生物科技有限公司(简称“阿法纳公司”)、合肥阿法纳安科生物科技有限公司联合申报的“AFN0328注射液”治疗恶性肿瘤的临床试验申请已获批准，获得同意开展治疗HPV16/18感染相关的子宫颈癌、肛门癌、外阴癌、阴道癌、阴茎癌、头颈部癌等的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","300009","BK0239","BK0042","BK1576","BK0070","BK1141","03347","BK1583"],"gpt_icon":0},{"id":"2452413131","title":"罗氏(RHHBY.US)双特异性抗体疗法Vabysmo临床试验结果显示长期疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2452413131","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452413131?lang=zh_cn&edition=full","pubTime":"2024-07-18 10:14","pubTimestamp":1721268842,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月18日，罗氏宣布了重磅双特异性抗体疗法Vabysmo治疗糖尿病性黄斑水肿的临床试验RHONE-X的四年新数据。长期研究的探索性结果显示，Vabysmo继续保持患者视力，并延长DME患者的治疗间隔时间。值得一提的是，4年后超过90%接受Vabysmo治疗的患者达到DME症状消失的标准。迄今为止，Vabysmo已在近100个国家和地区获批用于治疗DME和新生血管或湿性年龄相关性黄斑变性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1576","03165","BK4007","03347","BK1141","RHHBY"],"gpt_icon":0},{"id":"2452145296","title":"CRO概念盘中跳水，泰格医药跌1.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2452145296","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452145296?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:46","pubTimestamp":1721267206,"startTime":"0","endTime":"0","summary":"07月18日，CRO概念盘中跳水，截至09点46分，CRO概念整体指数下跌0.81%，报323.390点。从个股上来看，该概念的成分股中，泰格医药跌1.30%，义翘神州、昭衍新药、九洲药业跌幅居前。从资金上来看，截止发稿，CRO概念主力净流入为-5861.24万，其中康龙化成受到资金热捧，主力净流入626.75万；拉长时间线来看，该板块近20日主力资金净流入-26.33亿。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718094646af92de3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240718094646af92de3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","03347","BK1583"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tigermed.net","stockEarnings":[{"period":"1week","weight":0.1332},{"period":"1month","weight":0.0525},{"period":"3month","weight":0.028},{"period":"6month","weight":0.0944},{"period":"1year","weight":-0.2932},{"period":"ytd","weight":-0.0883}],"compareEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.048},{"period":"6month","weight":0.1092},{"period":"1year","weight":-0.0755},{"period":"ytd","weight":0.0345}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州泰格医药科技股份有限公司是一家从事为新药研发提供临床试验服务的中国控股公司。该公司经营两个分部。临床试验技术服务分部向生物制药和医疗器械公司提供临床试验运作服务和医学翻译等服务，帮助其进行创新药物、仿制药和医疗器械的临床试验。临床试验相关服务及实验室服务分部从事提供分析服务，比如数据管理和统计分析；后勤和执行支持服务，比如临床试验现场管理；行政协助，比如患者招募；以及咨询服务等。该分部同时通过其子公司为临床前和临床开发阶段提供实验室服务。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.100472},{"month":2,"riseRate":0.5,"avgChangeRate":-0.009715},{"month":3,"riseRate":0.75,"avgChangeRate":0.001867},{"month":4,"riseRate":0.25,"avgChangeRate":-0.03464},{"month":5,"riseRate":0.25,"avgChangeRate":-0.020185},{"month":6,"riseRate":0.5,"avgChangeRate":-0.014345},{"month":7,"riseRate":0.5,"avgChangeRate":-0.005457},{"month":8,"riseRate":0,"avgChangeRate":-0.091797},{"month":9,"riseRate":0.25,"avgChangeRate":-0.038231},{"month":10,"riseRate":0.5,"avgChangeRate":-0.01231},{"month":11,"riseRate":0.5,"avgChangeRate":0.046608},{"month":12,"riseRate":0.5,"avgChangeRate":0.063459}],"exchange":"SEHK","name":"泰格医药","nameEN":"TIGERMED"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰格医药,03347,泰格医药股票,泰格医药股票老虎,泰格医药股票老虎国际,泰格医药行情,泰格医药股票行情,泰格医药股价,泰格医药股市,泰格医药股票价格,泰格医药股票交易,泰格医药股票购买,泰格医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰格医药(03347)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰格医药(03347)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}